Oracle kicked off the year by launching its Oracle Life Sciences AI Data Platform, which it touted as using generative AI, ...

Ambrose Healthcare has bought AM-Pharma for up to 161 million euros ($181 million), inking a cut-price deal for the Dutch ...

Disc’s phase 3 trial provides a clearer link between the biomarker, whole-blood metal-free protoporphyrin IX (PPIX), and ...

AbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial. Skyrizi is a ...

Enlivex is laying off 60% of its workforce, ending preclinical R&D and trimming its top execs’ salaries as the Israeli ...

Last Friday, Frazier Life Sciences hit the Nasdaq with its second biotech-focused SPAC. TCGX is already on the hunt for ...

The pharmaceutical industry has traditionally viewed drug discovery and clinical development as separate stages of the R&D ...

Germany’s Merck KGaA has picked up Silence Therapeutics to the tune of $1.3 billion in the wake of the British biotech’s mid-stage success for its challenger to Takeda’s Mimrylo. The all-cash deal ...

Eli Lilly has formed a partnership with Hong Kong's Metis TechBio worth up to $1.1 billion, gaining access to an AI drug ...

A year after their first antibody-drug conjugate (ADC) team-up, Roche has returned to Hansoh Pharmaceutical for a mammoth $15 billion biobucks pact.

Nouscom has reeled in 120 million euros ($135 million) in series D funds to take a cancer-preventing vaccine through a ...

Gilead Sciences has notched a phase 2 win in ulcerative colitis (UC), with its once-daily pill emvistegrast outperforming ...